- איגודים
- אונקולוגיה
- אורולוגיה
- טיפול נמרץ
- מומחים צעירים
- מיילדות וגינקולוגיה
- משפחה
- נוירולוגיה
- עור ומין
- המטולוגיה
- חברות
- אורואונקולוגיה
- אם ועובר
- אנדוסקופיה גינקולוגית
- גידולי מערכת העיכול
- גיל המעבר
- החברה להפרעת קשב
- החברה לכאב ראש
- הפרעות תנועה
- טיפול בכאב
- טיפול פליאטיבי
- מחלות מטבוליות
- מלנומה
- סרטן השד
- סרטן ריאות
- רדיותרפיה
- רפואת אורחות חיים
מן הרשת
Treatment Based on Advanced Molecular Imaging Can Improve DFS in Prostate Cancer
The use of advanced molecular imaging with the PET radiotracer fluciclovine (18F) to inform treatment decisions can lead to improved disease-free survival (DFS) rates in patients with recurrent prostate cancer, according to data from the phase 2/3 EMPIRE-1 (NCT01666808) trial presented during the 2020 American Society for Radiation Oncology Annual Meeting
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
he efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) with PD-L1 expression are not known
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation–positive advanced non–small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) with PD-L1 expression are not known
FDA approves pralsetinib for lung cancer with RET gene fusions
On September 4, 2020, the Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
mong patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation
מחקרים וחדשות רפואה
-
מן הרשת14.06.2021, 11:53
-
מן הרשת14.06.2021, 11:52
-
מן הרשת14.06.2021, 11:51
-
מן הרשת14.06.2021, 11:50
7 הכי נקראות
-
1
-
2
-
3
-
4
-
5
-
6
-
7
תגובות אחרונות